Xilinx Reaches New 52-Week High (XLNX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Xilinx (Nasdaq: XLNX) hit a new 52-week high Wednesday as it is currently trading at $37.84, above its previous 52-week high of $37.74 with 378,485 shares traded as of 10:05 a.m. ET. Average volume has been 2.5 million shares over the past 30 days.

Xilinx has a market cap of $9.8 billion and is part of the technology sector and electronics industry. Shares are up 4.5% year to date as of the close of trading on Tuesday.

Xilinx, Inc. designs, develops, and markets programmable platforms worldwide. The company has a P/E ratio of 21.3, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Xilinx as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. You can view the full Xilinx Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Take Xilinx' Rally Seriously

Are the Semis Now on Shaky Ground?

Are the Semis Now on Shaky Ground?

Xilinx, Arena Pharmaceuticals, Magellan Midstream: 'Mad Money' Lightning Round

'I Love the Down-and-Outers': Cramer's 'Mad Money' Recap (Thursday 7/13/17)